Crippled Coronavirus: 5'-PolyU targeted Oligo prevents development of infectious Virions
Abstract
Current RNA viral pandemic of COVID-19 has been worsened by rapidly spreading viral variants. To inhibit mutation-based development of new escape variants, elements that are indispensable for the virus may be targeted. The 5-polyU tract of the antigenome offers one such target. Host cells do not harbor 5-polyU tracts on any of their transcripts, making the tract an attractive virus-specific target. We hypothesize that inhibiting the 5-polyU by complementary oligonucleotide can limit the use of the tract as template for virus to generate 3 polyA tails of RNA viruses. Here, we used a frameshift-inducing DNA oligonucleotide with 3 polyAs to target the 5-polyU tract of mouse coronavirus (MHV-A59). Results from assays for double stranded RNA (dsRNA) synthesis, infectivity of released virions, and syncytium formation indicate that the oligonucleotide treatment prevented generation of infectious virions. Our results show a unique mode of action of the designed 3-polyA oligonucleotide against mouse coronavirus which leaves host cells unaffected. This strategy can be adopted for the development of novel classes of oligonucleotide-based drugs that inhibit the production of infectious RNA viruses, including the coronaviruses. Since the 5-polyU tract is conserved and is essential for variants of coronaviruses, this strategy can potentially address coronavirus variant emergence as well.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Achilles' heel of coronaviruses: targeting the 5' Polyuridines tract of the antigenome to inhibit Mouse coronavirus-induced cell death
H. Ullah, S. Averick, Q. Tang·bioRxiv·Jul 26, 2021
- Physiologic RNA Targets and Refined Sequence Specificity of Coronavirus EndoU
R. Ancar, Y. Li, … D. L. Barton·bioRxiv·May 20, 2020
- Potential Opportunity Of Antisense Therapy Of COVID-19 on an in vitro model
A.N. Goryachev, S.A. Kalantarov, … A.S. Goryacheva·Современные проблемы науки и образованияPeer-reviewed·Jan 1, 2020
- Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation
- A guanidine-based coronavirus replication inhibitor which targets the nsp15 endoribonuclease and selects for interferon-susceptible mutant viruses
Benjamin Van Loy, Eugènia Pujol, … Annelies Stevaert·PLoS PathogensPeer-reviewed·Feb 11, 2025
- An intranasal ASO therapeutic targeting SARS-CoV-2
C. Zhu, J. Y. Lee, … A. M. Näär·bioRxiv·May 17, 2021